PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course
Visit https://www.peervoice.com/MWW860 to view the entire programme with slides. After completing “A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course”, participants will be able to: Analyse the most recent clinical evidence for androgen receptor (AR)-targeted therapies in the management of patients with metastatic hormone-sensitive prostate cancer (mHSPC); Describe current practice patterns and unmet needs in the management of patients with mHSPC; Formulate evidence- and expert-based management strategies for patients with mHSPC that maximise long-term outcomes.